Key result
This review evaluates the basic pharmacology, efficacy, safety, and clinical implications of ivabradine combined with recommended pharmacological therapy in chronic heart failure.
Why the study?
Does ivabradine combined with standard therapy improve outcomes in patients with chronic heart failure and reduced ejection fraction?
Does ivabradine combined with standard therapy improve outcomes in patients with chronic heart failure and reduced ejection fraction?
This review summarizes the pharmacology, efficacy, and safety of adding ivabradine to standard therapy in patients with chronic heart failure and reduced ejection fraction.
May inform ivabradine addition in HFrEF on standard therapy; leaves open need for updated RCTs in contemporary populations.
Several studies have underlined the beneficial effect of a lower heart rate on mortality in patients with chronic heart failure and reduced ejection fraction. In this context, the following review article will evaluate the benefit of a combination of the currently recommended pharmacological therapy in chronic heart failure (including β-blockers at optimal doses) with the selective heart rate reducing agent ivabradine. A summary of the basic pharmacology of ivabradine will precede the discussion of its efficacy and safety in clinical trials, as well as clinical implications.
No takes yet. Share an insight, caveat, or question.
Elzir et al. (2014) conducted a review in chronic heart failure and reduced ejection fraction. Ivabradine was evaluated. This review evaluates the basic pharmacology, efficacy, safety, and clinical implications of ivabradine combined with recommended pharmacological therapy in chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: